Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Impacto
Scholar |
Otros documentos de la autoría: Lorenzo, Miguel; Miñana, Gema; Palau, Patricia; Amiguet, Martina; Seller, Julia; García Pinilla, José Manuel; Villar, Sandra; De la Espriella, Rafael; Núñez, Eduardo; Górriz, José Luis; Valle, Alfonso; Bodí, Vicent; Sanchis, Juan; Bayes-Genis, Antoni; Núñez, Julio; DAPA-VO2 Investigators
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
https://doi.org/10.1016/j.cardfail.2023.02.008 |
Metadatos
Título
Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection FractionAutoría
Fecha de publicación
2023-05Editor
ElsevierISSN
1071-9164Cita bibliográfica
Lorenzo M, Miñana G, Palau P, Amiguet M, Seller J, Garcia Pinilla JM, Domínguez E, Villar S, De la Espriella R, Núñez E, Górriz JL, Valle A, Bodí V, Sanchis J, Bayés-Genis A, Núñez J; DAPA-VO2 Investigators. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction. J Card Fail. 2023; 29(5): 849-854. doi: 10.1016/j.cardfail.2023.02.008.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://www.sciencedirect.com/science/article/pii/S107191642300060X?casa_token=Y ...Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Background: We aimed to evaluate the effect of dapagliflozin on short-term changes in hemoglobin in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated the ... [+]
Background: We aimed to evaluate the effect of dapagliflozin on short-term changes in hemoglobin in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated the effect of dapagliflozin on functional capacity, quality of life and NT-proBNP levels.
Methods: This is an exploratory analysis of a randomized, double-blinded clinical trial in which 90 stable patients with HFrEF were randomly allocated to dapagliflozin or placebo to evaluate short-term changes in peak oxygen consumption (peak VO2) (NCT04197635). This substudy evaluated 1- and 3-month changes in hemoglobin levels and whether these changes mediated the effects of dapagliflozin on peak VO2, Minnesota Living-With-Heart-Failure test (MLHFQ) and NT-proBNP levels.
Results: At baseline, mean hemoglobin levels were 14.3 ± 1.7 g/dL. Hemoglobin levels significantly increased in those taking dapagliflozin (1 month: + 0.45 g/dL (P = 0.037) and 3 months:+ 0.55 g/dL (P = 0.012)]. Changes in hemoglobin levels positively mediated the changes in peak VO2 at 3 months (59.5%; P < 0.001). Changes in hemoglobin levels significantly mediated the effect of dapagliflozin in the MLHFQ at 3 months (-53.2% and -48.7%; P = 0.017) and NT-proBNP levels at 1 and 3 months (-68.0%; P = 0.048 and -62.7%; P = 0.029, respectively).
Conclusions: In patients with stable HFrEF, dapagliflozin caused a short-term increase in hemoglobin levels, identifying patients with greater improvements in maximal functional capacity, quality of life and reduction of NT-proBNP levels. [-]
Publicado en
Journal of Cardiac Failure, 2023, vol. 29, no 5Entidad financiadora
Astra Zeneca | Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network | CIBER Cardiovascular
Código del proyecto o subvención
ESR-17- 13447 | PT17/0017/0003 | PT20/00100 | 16/11/00420 | 16/11/00403 | 16/11/00486
Derechos de acceso
Copyright © Elsevier Inc. All rights reserved.
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- MED_Articles [667]